secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2026-08-04T12:02:40+00:00
Accession:  0001274737-26-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised
--------------------------------------------------------------------------------

- Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.
- Adjusted EBITDA loss narrowed to $0.1M from $1.7M; operating loss $1.7M vs $2.6M.
- AVISE CTD test volume +11% YoY; trailing 12-month ASP $446, up $18 (+4%).
- Full-year 2026 revenue guidance raised to $72-75M from prior $70-73M.
- Cash $24.6M; published study showing AVISE Lupus identified ~25% of SLE patients missed by conventional markers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/0001274737-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473726000047/exdx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001274737-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer